News Releases Year None2023202220212020201920182017 NuCana plc Announces Appointment of Adam George to its Board of Directors Apr 09, 2018 NuCana Reports Financial Results for the Year Ended December 31, 2017 Mar 21, 2018 NuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference Mar 02, 2018 NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer Jan 19, 2018 NuCana plc to Participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference Nov 20, 2017 NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer Nov 15, 2017 NuCana plc to Present at the Jefferies 2017 London Healthcare Conference Nov 02, 2017 NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs Oct 02, 2017 NuCana plc Announces Pricing of Initial Public Offering Sep 27, 2017 NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373 Sep 13, 2017 Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Next page next › Last page last »
NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer Jan 19, 2018
NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer Nov 15, 2017
NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs Oct 02, 2017
NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373 Sep 13, 2017